Clinical characteristics and survival outcomes in 269 patients with malignant pleural mesothelioma, split into training (n=169) and validation (n=100) sets
| Characteristic | Training set n (%) | Missing n (%) | Validation set n (%) | Missing n (%) | P value |
| Age | 73 (67–79) | 0 (0) | 72 (67–80) | 0 (0) | 0.877 |
| Gender | |||||
| Male | 136 (80.5) | 81 (81) | 1.000 | ||
| Not recorded | 0 (0) | 0 (0) | |||
| SIMD decile | 3.0 (1.0–8.0) | 17 (10) | 3.0 (1.0–8.0) | 15 (15) | 0.956 |
| Histological subtype | |||||
| Epithelioid | 108 (63.9) | – | 68 (68) | – | 0.895 |
| Biphasic | 12 (7.1) | – | 8 (8) | – | |
| Sarcomatoid | 33 (19.5) | – | 18 (18) | – | |
| Not recorded | 16 (9.5) | – | 6 (6) | – | |
| Performance status | 1.0 (0.0–2.0) | 49 (29) | 1.0 (1.0–2.0) | 27 (27) | 0.831 |
| EPS | 1.7 (1.1–2.3) | 53 (31) | 1.7 (1.7–2.3) | 27 (27) | 0.947 |
| CCI score | 2.0 (2.0–3.0) | 0 (0) | 2.0 (2.0–3.0) | 0 (0) | 0.730 |
| mGPS | 1.0 (1.0–2.0) | 32 (19) | 1.0 (1.0–2.0) | 17 (17) | 0.990 |
| Symptoms | |||||
| Weight loss | 2 (1.2) | – | 1 (1) | – | 1.000 |
| SOB | 81 (47.9) | – | 42 (42) | – | |
| Cough | 1 (0.6) | – | 0 (0) | – | |
| Chest pain | 22 (13) | – | 14 (14) | – | |
| Abdominal swelling | 3 (1.8) | – | 1 (1) | – | |
| SOB and chest pain | 16 (9.5) | – | 11 (11) | – | |
| Not recorded | 44 (26) | 31 (31) | |||
| Fluid LDH | 400 (240–680) | 62 (37) | 470 (260–890) | 38 (38) | 0.441 |
| Serum LDH | 190 (160–220) | 127 (75) | 190 (160–240) | 73 (73) | 0.319 |
| White cell count | 8.5 (7.1–11) | 8 (5) | 8.3 (6.8–11) | 3 (3) | 0.883 |
| Albumin | 32 (27–36) | 10 (6) | 32 (28–36) | 6 (6) | 0.801 |
| C-reactive protein | 41 (9.9–90) | 30 (18) | 35 (12–82) | 17 (17) | 0.624 |
| NLR | 4.2 (3.0–6.4) | 8 (5) | 4.1 (2.7–7.3) | 3 (3) | 0.842 |
| PLR | 240 (170–350) | 9 (5) | 250 (170–360) | 3 (3) | 0.884 |
| Aspirin use | 126 (74.6) | 0 (0) | 72 (72) | 0 (0) | 0.752 |
| Neutrophils | 6.0 (4.7–8.1) | 8 (5) | 5.7 (4.4–7.5) | 3 (3) | 0.831 |
| Lymphocytes | 1.4 (1.1–1.9) | 8 (5) | 1.3 (1.0–1.7) | 3 (3) | 0.898 |
| Platelets | 340 (260–430) | 9 (5) | 350 (240–420) | 3 (3) | 0.455 |
| Survival (days) | 270 (140–450) | 0 (0) | 220 (130–510) | 0 (0) | 0.522 |
Values are median (IQR). P values are for association tests between variables and allocation to training/validation sets.
CCI, Charlson Comorbidity Index; EPS, EORTC Prognostic Score; LDH, lactate dehydrogenase; mGPS, modified Glasgow Prognostic Score; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; SIMD, Scottish Index of Multiple Deprivation; SOB, shortness of breath.